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At a Glance Commentary 
Scientific Knowledge: Dysregulated inflammation in the cystic fibrosis (CF) lung is due, in part, 
to excessive protease activity. We have previously demonstrated the presence of the potent 
elastase, cathepsin S (CTSS), in the CF lung. However, the reasons for upregulated CTSS in the 
CF lung are unclear and its correlation to lung function in CF is unknown. 
What This Study Adds to the Field: We now show that CTSS activity and levels are significantly 
increased in CF regardless of infection status and correlate negatively with lung function. We 
also show that CTSS expression is significantly upregulated in CF airway epithelium due to 
altered miRNA-31 expression. These findings indicate that CTSS is a significant contributor to 
lung inflammation in the CF lung and may represent a viable therapeutic target in this setting. 
 
This article has an online data supplement, which is accessible from this issue’s table of content 
online at www.atsjournals.org. 
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Abstract 
Rationale: Cathepsin S (CTSS) activity is increased in bronchoalveolar lavage (BAL) fluid from 
cystic fibrosis (CF) patients. This activity contributes to lung inflammation via degradation of 
antimicrobial proteins such as lactoferrin and members of the -defensin family. Objectives: In 
this study, we investigated the hypothesis that airway epithelial cells are a source of CTSS, and 
mechanisms underlying CTSS expression in the CF lung. Methods: Protease activity was 
determined using fluorogenic activity assays. Protein and mRNA expression were analysed by 
ELISA, Western blotting and RT-PCR. Main Results: In contrast to neutrophil elastase, CTSS 
activity was detectable in 100% of CF BAL fluid samples from patients without Pseudomonas 
aeruginosa infection. In this study, we identified epithelial cells as a source of pulmonary CTSS 
activity with the demonstration that CF airway epithelial cells express and secrete significantly 
more CTSS than non-CF controls in the absence of pro-inflammatory stimulation. Furthermore, 
levels of the transcription factor IRF-1 correlated with increased levels of its target gene CTSS. 
We discovered that miR-31, which is decreased in the CF airways, regulates IRF-1 in CF 
epithelial cells. Treating CF bronchial epithelial cells with a miR-31 mimic decreased IRF-1 
protein levels with concomitant knockdown of CTSS expression and secretion. Conclusions: The 
miR-31/IRF-1/CTSS pathway may play a functional role in the pathogenesis of CF lung disease 
and may open up new avenues for exploration in the search for an effective therapeutic target.  
Word count: 231 
Key words: protease, microRNA, cystic fibrosis, epithelium 
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Introduction  
A major feature of the cystic fibrosis (CF) airways is the presence of free and active proteases, 
which are responsible for the destruction of lung tissue and other soluble proteins present in 
the respiratory tract. In CF, disruption of the protease-antiprotease balance has been 
demonstrated to be established by the age of 1 yr, and is thought to be sustained chronically 
thereafter (1). Lung remodelling is evident soon after diagnosis even in children diagnosed with 
CF following newborn screening (2–5). Furthermore, structural lung disease is progressive and 
is associated with worsening inflammation and pulmonary infection (6, 7). Neutrophil elastase 
(NE) is regarded as a key driver of lung destruction (3, 8) and inflammation especially during 
chronic Pseudomonas aeruginosa infection (9, 10). In contrast to NE, the role of cysteine 
cathepsins in CF has been relatively unexplored to date. 
In the last decade, attention to the role of cathepsin S (CTSS) in diseases such as cancer 
and heart disease has greatly increased (11, 12). We and others have previously reported the 
presence of members of the elastolytic cathepsin family including CTSS in cell-free CF lung 
secretions (13–16). In contrast to other cysteine cathepsin isoforms, CTSS can retain proteolytic 
activity after prolonged exposure to neutral pH in the extracellular environment, where it 
retains nearly as much elastase activity as NE (17–20). Consequently, in addition to pivotal roles 
in cellular events such as antigen processing (21), CTSS has the capacity to promote remodelling 
of the extracellular matrix via its potent elastinolytic activity. A recent report demonstrated the 
ability of CTSS to activate ENaC, which may be pathophysiologically relevant in inflammatory 
diseases such as CF (22). In addition, CTSS can cleave and inactivate key antimicrobials in the CF 
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airways including surfactant protein A (23), lactoferrin (14) and members of the β-defensin 
family (13). In contrast to NE, the cellular sources and role of CTSS in the CF lung has been 
relatively unexplored to date.  
In this study, we expand our previous investigations into the presence and activity of 
CTSS in the CF lung with a focus on young CF patients. A range of epithelial dysfunctions have 
been implicated in the pathogenesis of CF lung disease which are ultimately consequences of 
mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Given that 
epithelial cells have been reported to express CTSS (21, 24, 25), we investigated the hypothesis 
that CF airway epithelial cells contribute to the protease burden of the CF lung by releasing 
increased levels of CTSS compared to non-CF controls, and explore the mechanism responsible 
for our observations. Some of the results of these studies have been previously reported in the 
form of abstracts (26, 27). 
 
Methods  
Full details are available in the online data supplement. 
 
Bronchoalveolar lavage fluid samples and study approval 
Group 1 Paediatric CF subjects  
BAL fluid samples were obtained from 26 patients (0.7 - 18 yr, mean age 10.84 yr) diagnosed 
with CF; 11 with P. aeruginosa infection (Ps+) and 15 without (Ps-), as described previously (9). 
We refer readers to (9) and Table E1 in the online data supplement for further clinical 
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information, cell counts and details of pathogens detected in this cohort of patients. Ethical 
approval was obtained from the institutional review board of the Adelaide and Meath Hospital 
incorporating the National Children's Hospital with all parents providing written informed 
consent prior to participation.  
 
Group 2 Pre-school CF and non-CF subjects 
BAL fluid was obtained from Pseudomonas negative children with CF (n = 43; 0.9 - 5 yr, mean 
age 2.91 yr) through the SHIELD (Study of Host Immunity and Early Lung Disease in CF) CF study. 
In addition, 9 children who did not have CF (0.9 - 3 yr, mean age 1.73 yr) were included as a 
non-CF control group. Children in this control group were undergoing clinically indicated BAL 
for a variety of reasons, most commonly a history of recurrent respiratory infection, 
haemoptysis or cough. Details of pathogens detected and cell counts in the CF and non-CF BAL 
fluid and CF genotype details are presented in Table E2 in the online supplement. Ethical 
approval was obtained from the institutional review board of Our Lady's Children's Hospital 
Crumlin with all parents providing written informed consent prior to participation.  
 
Primary bronchial epithelial cell culture and study approval 
Primary cultures of well-differentiated human bronchial epithelial cells (PBECs) were obtained 
from patients with CF (n = 8) and from non-CF (n = 8) healthy volunteers and grown at the air-
liquid interface (28). The use of human tissues was approved by the University of Iowa 
Institutional Review Board.   
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Bronchial brush analysis and study approval 
Following informed consent under a protocol approved by Beaumont Hospital Institutional 
Review Board, bronchial brushings were sampled from patients with CF (n = 5) and non-CF (n = 
5) volunteers.  
 
Epithelial cell lines 
The human bronchial epithelial cell line 16HBE14o- (HBE), the CF bronchial epithelial cell line 
CFBE41o- homozygous for the F508del mutation (CFBE), the human tracheal epithelial cell line 
9HTEo- (HTE), and the CF tracheal epithelial cell line CFTE29o- homozygous for the F508del 
mutation (CFTE) were obtained as a gift from Prof. Dieter Gruenert (California Pacific Medical 
Centre Research Institute, San Francisco, CA) (29, 30). Cell lines were maintained in Minimum 
Essential Medium (Life Technologies Ltd., Paisley, UK), supplemented with 10% heat-inactivated 
foetal bovine serum (FBS, Life Technologies Ltd.), 2mM L-glutamine and 1% 
penicillin/streptomycin (PAA Laboratories GmbH, Austria) at 37°C under 5% CO2. 
 
Statistical analysis 
All data were analysed using GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA) and 
are reported as mean ± SEM or median (IQR) where appropriate. Results are representative of 
at least n = 3 unless otherwise indicated. Means were compared by unpaired t-test, Mann 
Whitney test, one-way analysis of variance (ANOVA) or Kruskal-Wallis test as appropriate. P < 
0.05 was accepted to indicate statistical significance. The relationships between clinical 
parameters were verified using Spearman correlation.  
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Results  
Increased CTSS in the CF lung correlates negatively with lung function in a paediatric CF 
patient cohort 
We previously reported the presence of active CTSS in the CF lung (13, 14). In this study, we 
expanded these observations by first comparing CTSS activity and levels in BAL fluid from a 
cohort of paediatric CF patients stratified on the basis of the absence (Ps-; n = 15) or presence 
(Ps+; n = 11) of chronic P. aeruginosa infection as described previously (9). Details of pathogens 
detected in this CF cohort are presented in Table E1 in the online supplement. In agreement 
with previous work (16), there was no significant difference in either CTSS activity or CTSS levels 
in Ps+ compared with Ps- CF BAL, which supports the suggestion that CTSS may not be not a 
reliable marker of P. aeruginosa infection in CF. However, both CTSS activity (Figure 1C; r = -
0.56; P = 0.0069) and CTSS levels (Figure 1D; r = -0.58; P = 0.0048) correlated negatively with 
FEV1 (% predicted) suggesting that increased CTSS is associated with a decline in lung function 
in CF. In addition, CF BAL fluid CTSS activity was found to correlate significantly with BAL 
neutrophil counts (Figure 1E; r = 0.6875; P = 0.0001) but not with macrophage counts (Figure 
1F; r = 0.2759; P = 0.1725). 
 
CTSS is readily detectable in BAL fluid from pre-school CF patients 
Our recent findings demonstrate that in CF lung secretions, the level of active NE is significantly 
increased in Ps+ compared to Ps- CF BAL fluid and sputum (9, 10). In contrast, CTSS activity and 
levels were found to be significantly elevated in CF BAL fluid regardless of the status of chronic 
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Pseudomonas infection (Figure 1A-B). Therefore, in order to extend our analysis of CTSS and NE 
activities in young CF patients without chronic P. aeruginosa infection, BAL fluid samples were 
obtained from a cohort of pre-school children with CF (n = 43) who tested negative for P. 
aeruginosa infection. In addition, BAL fluid was obtained from Pseudomonas negative non-CF 
children (n = 9).  Details of pathogens detected in this cohort of CF and non-CF patients are 
presented in Table E2 in the online supplement. As illustrated in Figure 2A, the levels of CTSS 
activity were significantly increased in CF BAL compared to BAL samples from children without 
CF (P < 0.05). In contrast, no significant difference in NE activity (Figure 2B) was detectable 
between the non-CF and CF BAL samples (P = 0.562). Interestingly, while CTSS activity as 
detectable in all CF and non-CF BAL samples, NE activity was undetectable in the majority of 
samples from both groups (66.7% non-CF; 60.5% CF). This level of detection of NE is in 
agreement with previous reports in the literature (3, 7, 31). In agreement with our findings 
above, CF BAL fluid CTSS activity was found to correlate significantly with BAL neutrophil counts 
(Figure 2C; r = 0.4806; P = 0.0015) but not with macrophages (Figure 2D; r = 0.2522; P = 0.1165).  
 
Expression and secretion of CTSS from unstimulated CF and non-CF epithelial cells 
Evidence to date suggests that CTSS has a restricted tissue distribution with predominant 
expression in antigen presenting cells; however, more recent work has demonstrated 
expression of CTSS in airway epithelial cells (24, 25, 32). Given the prevalence of CTSS in the 
lungs of children with CF, we investigated whether pulmonary epithelial cells represent a 
possible source of CTSS in the CF lung. As illustrated in Figure 3, unstimulated CF tracheal 
(Figure 3A) and bronchial (Figure 3B) epithelial cell lines secreted significantly elevated levels of 
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active CTSS compared to non-CF cells. These findings were consistent in well-differentiated 
primary human bronchial epithelial cells (PBECs) as increased levels of extracellular CTSS 
activity were detected in both CF apical washes and basolateral media compared to non-CF 
(Figure 3C-D). These findings were consistent with findings by ELISA (Figure 3E-H) and Western 
blotting (Supplemental Figure E1) demonstrating that CF airway epithelial cells secrete more 
CTSS compared to non-CF controls. We next examined the levels of CTSS mRNA in these cells by 
RT-PCR. In concurrence with the protein data, CTSS expression was found to be elevated in CF 
tracheal and bronchial epithelial cell lines (CFTE, CFBE) compared to non-CF controls (HTE, HBE; 
Figure 4A). These findings were confirmed in PBECs, with significantly increased CTSS mRNA 
levels detectable in CF PBECs compared to non-CF (Figure 4B-C). In contrast to CTSS, no changes 
in cathepsin B (CTSB) expression were found between CF and non-CF epithelial cells 
(Supplemental Figure E2).  
 
Increased levels of IRF-1 as a result of miR-31 deregulation result in increased expression and 
secretion of CTSS by CF epithelial cells 
A number of transcription factors are reported to regulate the expression of CTSS. Of particular 
interest is IRF-1, which has been shown to regulate CTSS expression in airway epithelial cells 
(25). Therefore, we investigated the status of IRF-1 in whole cell lysates of CF and non-CF cells 
by Western blotting. Levels of IRF-1 were found to be elevated in CF compared to non-CF 
epithelial cell lines and consistent between tracheal and bronchial cell types (Figure 5A). 
Furthermore, levels of IRF-1 were significantly increased in CF PBECs compared to non-CF 
(Figure 5B-C). In order to establish a functional relationship between IRF-1 and CTSS in CF 
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epithelial cells, we used short interfering RNA (siRNA) to knock down IRF-1 levels in CFBEs and 
examined the effects on CTSS levels. As illustrated in Figure 6A, transfection of CFBEs with IRF-1 
siRNA effectively decreased IRF-1 protein levels compared to mock transfected (Con) and the 
scrambled control (Scr). This decrease in IRF-1 protein was associated with a marked reduction 
in CTSS expression (Figure 6B) but not CTSB (Supplemental Figure E3). Consistent with the 
reduced expression of CTSS, both extracellular CTSS activity (Figure 6C) and levels (Figure 6D) 
were significantly decreased in CFBEs transfected with IRF-1 siRNA compared to Scr controls, 
demonstrating the functional importance of IRF-1 in CFBE CTSS expression.  
To elucidate the mechanism responsible for increased levels of IRF-1 protein in CF 
epithelial cells, we considered the role of microRNAs (miRNAs). MiR-31 is one of the most 
highly expressed miRNAs present in human non-CF primary well-differentiated airway epithelial 
cultures (33) and in silico analysis predicted that IRF-1 was a target of miR-31. Both 
microRNA.org and TargetScan 6.2 predicted two binding sites for miR-31 located at positions 
606-613 (8mer, mirSVR score -0.8544) and 2182-2187 (7mer-1A, mirSVR score -0.001) of the 
IRF-1 3’ UTR (Supplemental Figure E4). MiR-31 is not predicted to target CTSS mRNA. MiR-31 
was found to be significantly decreased in CF bronchial brushings compared to non-CF using 
Taqman MicroRNA Arrays v2.0 (34). Relative expression of miR-31 was validated independently 
by qRT-PCR in separate cohorts of CF and non-CF individuals (n = 5) and, in agreement with 
previous data (34), miR-31 expression was significantly decreased in CF bronchial brushings 
compared to non-CF (Figure 7A).  
Similarly, a consistent decrease in miR-31 expression was observed in CF PBECs (n = 4; 
Figure 7B) and both tracheal (Figure 7C) and bronchial (Figure 7D) epithelial cell lines compared 
11 
 
to non-CF controls. We next assessed the effect of miR-31 overexpression on CFBE IRF-1 and 
CTSS levels. Transfection of CFBEs with pre-miR-31 (PM-31) led to a significant increase in 
mature miR-31 compared with mock or negative control (PM-Neg) transfected cells (data not 
shown). As illustrated in Figure 8A, transfection of PM-31 into CFBE cells resulted in a decrease 
in the levels of IRF-1 detectable by Western blot compared to mock transfected (Con) cells or 
cells transfected with PM-Neg. This decrease in IRF-1 was associated with a significant decrease 
in both CTSS expression (Figure 8B) and secretion (Figure 8C) in CFBEs overexpressing miR-31 
compared to controls. 
 
Discussion 
In this report, our findings show that CTSS is a highly abundant protease found in the CF lung, 
even in young children with CF in the absence of chronic Pseudomonas infection. We have 
demonstrated that CF pulmonary epithelial cells may contribute to the protease burden of the 
CF lung by expressing and releasing increased levels of active CTSS. Although we have described 
epithelial cells as a potential source of CTSS in the CF airway, other cell types such as 
neutrophils and macrophages may also contribute to the CTSS levels found in CF BAL fluid. In 
this study, we found that CF BAL fluid CTSS activity correlated significantly with BAL neutrophil 
counts, but not macrophage counts. However, further work is required to delineate the 
contribution of various cell types to pulmonary CTSS load. In addition, the significant correlation 
observed also supports the hypothesis that proteases such as CTSS may also play a role in 
neutrophil recruitment as proposed previously (35).  
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Further investigation identified miR-31 as a potentially important regulator of CTSS 
expression via the transcription factor IRF-1 in CF epithelial cells. MiRNAs are short non-coding 
RNAs that modulate target gene expression via translational repression or degradation of their 
target RNAs (36). MiRNAs may regulate up to one-third of all protein coding genes in human 
genome (37) and it is believed that dysregulation of miRNAs can contribute to disease 
pathology (38). Recent work has identified unique miRNA profiles in the CF lung and analysis of 
target genes has revealed important roles for miRNAs in the regulation of CFTR expression and 
function and inflammation (34, 39, 40). MiR-31 is one of the most highly expressed miRNAs 
present in human non-CF airway epithelial cells (33) and our data demonstrate that miR-31 
expression was significantly decreased in CF airway epithelial cell lines and primary cells. 
Altered miR-31 expression has been reported in diseases such as cancer, psoriasis, coronary 
artery disease and lupus (41–44), however, the mechanisms of this dysregulation are poorly 
understood.  
Similar to other human genes, miRNA expression can be altered by several mechanisms, 
such as chromosomal abnormalities, mutations, defects in their biogenesis machinery, 
epigenetic silencing (DNA methylation, histone modification), or by transcription factors. Work 
to date suggests that miR-31 expression is regulated by a number of distinct signalling networks 
in an intricate lineage- and cell type-dependent manner (41). MiR-31 expression levels can be 
enhanced by TNF, bone morphogenetic protein-2 and TGF-β1 and by the transcription factor 
C/EBP-β (42, 45–47). Other work has found that miR-31 is subject to epigenetic and non-
epigenetic silencing in different human breast cancer cell lines (41, 48). In addition, reduced 
mature miR-31 levels may arise due to the defective post-transcriptional processing of the miR-
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31 RNA precursor rather than transcriptional repression of the miR-31 gene itself (49). Further 
work is required to elucidate the cause of decreased miR-31 in the CF lung and how this relates 
to CFTR dysfunction. 
Altered miR-31 expression has been reported in diseases such as cancer and psoriasis, 
and a number of target genes have been identified including RhoA, PP2A regulatory subunit B 
alpha isoform and serine/threonine kinase 40 (41, 42, 50). In this study, we implicate the 
transcription factor IRF-1 as a novel target of miR-31. IRF-1 plays an important role in the 
regulation of cellular responses in host defence such as the innate and adaptive immune 
responses, antigen presentation and cellular apoptosis (51). Of interest, increased IRF-1 
expression has also been documented in CF blood polymorphonuclear leukocytes (PMNs) 
compared to non-CF PMNs (52) but the role of miRNAs in this up-regulation and the 
downstream effects of increased IRF-1 on neutrophil function are currently unknown.  
Neutrophil-dominated inflammation has been shown to play a major role in the 
pathogenesis of CF lung disease. Work to date has highlighted an association between NE and 
bronchiectasis (3) and disease severity (8) in young children with CF. Although we found that 
CTSS was active in a greater number of BAL fluid samples compared to NE, our NE findings 
correlate closely with those of Sly and colleagues who demonstrated that approximately 18-
41% of CF BAL fluid samples from similar age groups contained active NE (3, 31). Our recent 
findings demonstrate that in CF lung secretions, the level of active NE is significantly increased 
in patients with chronic Pseudomonas infection compared to Pseudomonas negative CF 
patients (9, 10). These findings are in contrast to the profile of CTSS observed in these patients 
where BAL fluid CTSS was found to be significantly elevated regardless of the status of chronic 
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Pseudomonas infection compared to healthy control BAL fluid. The findings from this cross-
sectional investigation also demonstrate the presence of active CTSS in BAL fluid from young CF 
patients and raise the important question of the potential role of CTSS in CF lung disease.  
Previous work indicates that CTSS may also play a role in the diminution of the lung’s 
antimicrobial defences thereby favouring conditions for bacterial infection (13, 14, 23). 
Furthermore, given its potent elastinolytic activity (17–20, 53), it is possible that CTSS may play 
a role in tissue damage and remodelling present in early CF (2, 3, 6, 7), an increasingly 
recognized clinical finding over the last 5 years. In addition, the presence of elevated CTSS in 
the CF airways may explain, in part, why previous therapeutic approaches to protease 
neutralisation in the CF lung, which have not taken elevated CTSS activity into account, have 
not been entirely successful to date. At present, there is no available therapy to prevent, limit 
or reverse airway remodelling. Further work, including longitudinal analysis of CF patients, will 
be essential to elucidate the role of CTSS in the pathogenesis and progression of CF lung 
disease. 
In conclusion, these novel data not only identify pulmonary epithelial cells as a source of 
CTSS in the CF lung, but also highlight a mechanism for the increased CTSS via dysregulated 
miRNA expression, which may represent a link between epithelial CFTR dysfunction and CF lung 
disease. Because of its multiple biological functions, CTSS may play an important role in the 
pathogenesis of lung disease in CF. These findings may have important implications with regard 
to the pathogenesis of CF lung disease as well as the development of therapeutics in the future 
aimed at limiting the progression of structural lung disease or preserving lung function in 
individuals with CF. 
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Figure Legends 
Figure 1. Increased CTSS levels and activity in CF BAL fluid correlate negatively with lung 
function.  
(A) CTSS activity in BAL fluid from a cohort of paediatric Pseudomonas-infected (Ps+; n = 15) and 
non-infected (Ps-; n = 11) CF patients (Group 1) was determined using the fluorogenic FR-AMC 
substrate (pH 7.5). Results were expressed as the change () in relative fluorescence units 
(RFU) over time. (B) Total CTSS levels (tCTSS) in Ps- and Ps+ CF BAL fluid were quantified by 
ELISA. There was no significant difference between Ps- and Ps+ CF BAL fluid for either parameter 
measured. The correlation between CF BAL fluid (C) CTSS activity and (D) tCTSS levels and FEV
1
 
(n = 22) was determined using Spearman correlation. The correlation between CF BAL fluid CTSS 
activity and (E) neutrophils and (F) macrophages were determined using Spearman correlation.  
 
Figure 2. Profile of CTSS and NE activity in BAL fluid from non-CF and CF children who tested 
negative for Pseudomonas. 
(A) CTSS and (B) NE activity were quantified in BAL fluid from a cohort of pre-school, 
Pseudomonas negative non-CF (n = 9) and CF children (n = 43; Group 2). CTSS and NE activities 
were detected using the fluorogenic substrates FR-AMC (pH 7.5) and AAPV-AMC, respectively. 
Results were expressed as the change () in relative fluorescence units (RFU) over time. CTSS 
activity was detectable in all 43 CF samples analysed, however, in contrast, NE activity was 
undetectable in the majority of samples (>60%). The correlation between CF BAL fluid CTSS 
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activity and (C) neutrophils and (D) macrophages were determined using Spearman correlation. 
* = P < 0.05.  
 
Figure 3. Basal CTSS secretion from unstimulated human CF and non-CF pulmonary epithelial 
cells.  
CTSS activity in cell-free supernatants of non-CF and CF (A) tracheal (HTE, CFTE) and (B) 
bronchial epithelial (HBE, CFBE) cell lines and (C) primary human bronchial epithelial cells (PBEC, 
n = 4) apical washes and (D) basolateral media was analysed using FR-AMC (pH 7.5). Results 
were expressed as the change () in relative fluorescence units (RFU) over time. (E-H) Total 
CTSS (tCTSS) levels in cell line supernatants, PBEC apical washes and PBEC basolateral media 
were quantified by ELISA. ** = P < 0.01, *** = P <0.001.  
 
Figure 4. Increased basal CTSS mRNA expression in CF epithelial cells.  
(A) CTSS and GAPDH expression were detected in tracheal (HTE, CFTE) and bronchial epithelial 
(HBE, CFBE) cell lines and (B) primary human bronchial epithelial cells (PBEC, n = 4) by RT-PCR. 
(C) Densitometry of PBEC CTSS relative to GAPDH. * = P < 0.05.  
 
Figure 5. IRF-1 levels in non-CF and CF epithelial cells.  
(A) Western blotting of IRF-1 and GAPDH in tracheal (HTE, CFTE) and bronchial (HBE, CFBE) 
epithelial cell lines and (B) PBEC (n = 4) whole cell lysates. (C) Densitometry of PBEC IRF-1 
relative to GAPDH. ** = P < 0.01.  
 
18 
 
Figure 6. IRF-1 knockdown decreases CTSS expression and secretion from CF epithelial cells. 
The effects of IRF-1 knockdown on CTSS levels in CFBEs were investigated using IRF-1 siRNA. 
CFBEs were transfected with 100 nM IRF-1 siRNA (IRF-1), scrambled control (Scr) or mock 
transfected (Con) for 48 hr. After a further 24 hr incubation in fresh media, (A) knockdown of 
IRF-1 levels was confirmed by Western blotting and (B) CTSS mRNA levels were assessed by RT-
PCR. (C) Extracellular CTSS activity was determined using the FR-AMC (pH 7.5) substrate and (D) 
extracellular tCTSS levels were quantified by ELISA. The data are the mean ± SEM of n = 3 and 
are expressed as % of mock transfected control cells (C-D). ** = P < 0.01, *** = P <0.001.  
 
Figure 7. MiR-31 expression is decreased in CF epithelial cells.  
MiR-31 levels in (A) bronchial brushings (n = 5), (B) PBECs (n = 4), (C) tracheal and (D) bronchial 
epithelial cell lines were quantified by qRT-PCR and normalised to miR-16. * = P < 0.05, ** = P < 
0.01, *** = P <0.001.  
 
Figure 8. miR-31 dysregulation in CF epithelial cells leads to increased CTSS expression via IRF-
1.  
The effects of pre-miR-31 overexpression on IRF-1 and CTSS levels were determined by 
transfecting CFBEs with 30 nM pre-miR-31 (PM-31), negative control (PM-Neg) or mock 
transfected (Con) for 48 hr. (A) IRF-1 levels in whole cell lysates were analysed by Western 
blotting. (B) CTSS mRNA levels were assessed by RT-PCR. (C) Extracellular CTSS was quantified 
by ELISA. The data are the mean ± SEM of n = 3 and are expressed as % of mock transfected 
control cells. *** = P <0.001.  
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